Medicine. Rosatom has started preclinical studies of a new radiopharmaceutical for the treatment of cancer. A targeted drug based on the thorium-227 isotope and antibodies is intended for the treatment of prostate cancer. Due to its nuclear-physical properties, the thorium-227 isotope has a high potential for effective treatment of malignant neoplasms, including bone metastases, which often occur in prostate cancer. The research will continue until mid-2024.